University of Wisconsin
School of Medicine and Public Health

Rui Lab Publications

Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L. PRMT5 is upregulated by B cell receptor signaling and forms a positive feedback loop with PI3K/AKT in lymphoma cells. Leukemia. May 23, 2019.

Lu L, Zhu F, Li Y, Kimpara S, Hoang NM, Pourdashti S, Rui L. Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors. Blood Cancer J. 2019; 9(4):43.

Invited review article Zhu F and Rui L. PRMT5 in gene regulation and hematologic malignancies. Genes & Diseases. June 19, 2019.

Lu L*, Zhu F*, Zhang M*, Li Y, Drennan AC, Kimpara S, Rumball I, Selzer C, Cameron H, Kellicut A, Kelm A, Wang F, Waldmann TA#, Rui L#. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. (Epub ahead of print January 2, 2018). (*joint first authors, #joint corresponding authors).

Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer Journal. 2017; 7(12):632.

Zhu F, Hwang B, Miyamoto S, and Rui L. Nuclear import of JAK1 is mediated by a classical NLS and is required for survival of diffuse large B-cell lymphoma. Mol Cancer Res. 2016 Dec 28.

Rui L*#, Drennan AC*, Ceribelli M*, Zhu F, Wright GW, Huang DW, Xiao W, Li Y, Grindle KM, Lu L, Hodson DJ, Shaffer AL, Zhao H, Xu W, Yang Y, and Staudt LM#. Epigenetic gene regulation by Janus kinase 1 in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. (Online Oct 31, 2016) (*joint first authors, #joint corresponding authors). (Editors’ Choice by Alexandra Mushegian in Science Signaling 22 Nov, 2016: A noncanonical role for Janus kinase 1 in lymphoma).

Li Y*, Bouchlaka MN*, Wolff J, Grindle KM, Lu L, Qian S, Zhong X, Pflum N, Jobin P, Kahl BS, Eickhoff JC, Wuerzberger-Davis SM, Miyamoto S, Thomas CJ, Yang DT#, Capitini CM#, Rui L#. FBXO10 Deficiency and BTK Activation Upregulate BCL2 Expression in Mantle Cell Lymphoma. Oncogene (online, May 9, 2016). (*joint first authors, #joint corresponding authors).

Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, Yang Y, Webster DE, Rui L, Kohlhammer H, Nakagawa M, Waldmann TA, Staudt LM. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Natl Acad Sci U S A 2016; 113(14): 2039-2046.

Zheng M, Turton KB, Zhu F, Li Y, Grindle KM, Annis DS, Lu L, Drennan AC, Tweardy DJ, Bharadwaj U, Mosher DF*, Rui L*. A mix of S and ΔS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture. Oncogenesis. 2016 Jan 4;4:e184. (joint corresponding authors).

Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015 Dec 14;212(13):2189-201.

Chiorazzi M*, Rui L*, Yang Y, Ceribelli M, Tishbi N, Maurer CW, Ranuncolo SM, Zhao H, Xu W, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Shaham S, Staudt LM. Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3943-8. (joint first authors).

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011 Mar 17;471(7338):377-81.

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010 Dec 14;18(6):590-605. (Preview in the same issue of Cancer Cell; Highlighted in Hematology, May 2011).

Rui L*, Healy JI*, Blasioli J, Goodnow CC. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation. J Immunol. 2006 Oct 15;177(8):5337-46. (joint first authors).

Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, Yu D, Domaschenz H, Whittle B, Lambe T, Roberts IS, Copley RR, Bell JI, Cornall RJ, Goodnow CC. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005 May 26;435(7041):452-8.

Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol. 2003 Jun;4(6):594-600.

Invited Review Articles:

Drennan AC,  Rui L. HiJAKing the epigenome in leukemia and lymphoma. Leukemia & lymphoma. 2017; 58(11):2540-2547.

England CG, Rui L, Cai W. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. European Journal of Nuclear Medicine and Molecular Imaging. 2017; 44(3):517-532.

Rui L. The JAK-STAT pathway and hematological malignancy: beyond STATs (Editorial). Journal of Hematology & Transfusion 2013; 1(1): 1002.

Rui L, Schmitz R, Ceribelli M, Staudt LM. Malignant pirates of the immune system. Nat Immunol. 2011 Sep 20;12(10):933-40. Review.

Rui L,Goodnow CC. Lymphoma and the control of B cell growth and differentiation. Curr Mol Med. 2006 May;6(3):291-308. Review